Fosamax and Osteonecrosis of the Jaw: Understanding the Pathophysiology and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

The legacy context of general health and science information has long emphasized broad wellness principles, disease prevention, and the communication of medical knowledge to diverse audiences. Within this framework, public health messaging traditionally focused on lifestyle factors, nutrition, and common therapeutic interventions, often without deep scrutiny of specific pharmaceutical mechanisms. This heritage established a foundation for understanding how medications interact with physiological systems, but it typically addressed risks in generalized terms. Transitioning from this broad perspective, a more targeted occupational exposure concern emerges when considering the clinical use of bisphosphonates such as Fosamax. In mass production environments, where workers may handle or administer these compounds, the shift from general health education to specific risk awareness becomes critical. The focus narrows to understanding how prolonged exposure to such agents—whether through manufacturing, packaging, or healthcare administration—could influence tissue response. This pivot requires examining the interface between pharmaceutical chemistry and biological systems, particularly in the oral cavity, where bone remodeling processes are susceptible to disruption. The concern moves from abstract health literacy to concrete occupational safety, emphasizing the need for protective protocols and monitoring in settings where repeated contact with these substances occurs. Thus, the legacy of general health information now serves as a springboard for specialized risk assessment in occupational contexts.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the need for targeted risk awareness, this section examines the specific link between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. However, this suppression of normal bone remodeling has been linked to a serious adverse effect: osteonecrosis of the jaw. ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The pathophysiology of how Fosamax triggers ONJ involves several mechanistic pathways. Bisphosphonates, including alendronate, accumulate in bone tissue, particularly in areas of high bone turnover such as the jaw. The jawbone has unique structural and metabolic properties that may make it more susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including postmenopausal osteoporosis and bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research, conducted in estrogen-deficient rats, examined the effects of bisphosphonate (alendronate), parathyroid hormone, and their combination on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). The findings suggest that bisphosphonate treatment alters the mechanical and material properties of the jawbone, potentially predisposing it to necrosis.

Clinical Presentation and Risk Factors

The clinical presentation of ONJ typically involves exposed bone in the oral cavity that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, with risk factors including invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates causation assessment, as symptoms may appear shortly after initiation or after prolonged use. Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in typical trial populations.

Causation Considerations and Warnings

Causation-related considerations for affected patients include the multifactorial nature of ONJ. While Fosamax is a known risk factor, other elements such as dental procedures, infection, and comorbidities often contribute. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of bisphosphonate use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, detailing risk factors and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the rarity of ONJ and its association with other risk factors may lead to under-recognition. Patients should be informed of the signs and symptoms of ONJ, and dental evaluations are recommended before initiating bisphosphonate therapy, especially in those with risk factors. In summary, Fosamax can trigger osteonecrosis of the jaw through its suppression of bone remodeling, which alters jawbone properties and impairs healing. The condition is rare but serious, with onset ranging from days to months after starting the drug. Risk is increased by dental procedures, comorbidities, and longer exposure. Warnings in the prescribing information provide guidance, but clinical vigilance remains essential for early detection and management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) suppresses bone resorption by inhibiting osteoclast activity, which reduces bone turnover. This suppression alters the mechanical and material properties of the jawbone, predisposing it to necrosis. Bisphosphonates accumulate in areas of high bone turnover like the jaw, impairing healing and leading to exposed bone (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk increases with longer duration of bisphosphonate use.

How long after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates causation assessment, as symptoms may appear shortly after initiation or after prolonged use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.